08/30/2026
One of the most debilitating effects of CKD (chronic kidney disease) is sleep disruption.
Rusty Garrison has severe restless leg syndrome. It started mild about 3 years ago. Today, it impacts his entire body amd starts in the late afternoon when he is sitting.
His entire body twitches, and he gets no relief. He has went to a few of his doctors, even one of my spine specialists to see if he has a pinched nerve. Its simply and unfortunately a side effect he is dealing with.
Not sleeping well is a snowball effect, for him and honestly anyone. Sometimes his best sleep is in the morning as late as 7am. Sometimes he doesn't sleep at all, and what's sad is he tries to be quiet and do things to help me sleep. This isn't about me, but, his sleep disturbance spills over to me often :( I love him and will not leave his side, as we dont know when he may ever meed me in a urgent situation.
This article helps to offer ideas for sleep support. Sharing as it can help anyone!
https://www.facebook.com/share/1HnPjC9B9C/
Sleep disturbance affects between 50% and 80% of patients with chronic kidney disease - making it one of the most prevalent but least addressed symptoms in nephrology. Kidney patients are significantly less likely to receive sleep evaluation and treatment than the general population, despite experiencing sleep disorders at dramatically higher rates. This post covers why CKD destroys sleep, and what specific strategies can help.
📌 THE SPECIFIC SLEEP DISORDERS THAT AFFECT KIDNEY PATIENTS
RESTLESS LEGS SYNDROME (RLS): The most common sleep-related disorder in CKD, affecting approximately 20-30% of patients and up to 60-70% of dialysis patients. RLS causes an irresistible urge to move the legs, typically worse in the evening and at rest, transiently relieved by movement. It is directly caused by uraemic toxin accumulation and iron deficiency - both of which are central features of CKD. It prevents sleep onset and causes profound sleep fragmentation. Management: dialysis adequacy improvement, iron supplementation (IV iron in dialysis patients where applicable), and if severe, dopaminergic agents (pramipexole, ropinirole) under medical supervision - noting that these require dose adjustment in CKD. Gabapentin at low, CKD-appropriate doses is also used for RLS in kidney patients. SLEEP APNOEA: Both obstructive sleep apnoea (OSA) and central sleep apnoea (CSA) are significantly more prevalent in CKD patients than the general population. Fluid redistribution in CKD (fluid shifts from legs to upper body and neck when lying down) increases pharyngeal obstruction in OSA. CSA in CKD patients is linked to altered chemoreceptor sensitivity from uraemia and metabolic acidosis. Sleep apnoea is independently associated with faster CKD progression and cardiovascular events. If you snore loudly, experience witnessed apnoeic pauses during sleep, or wake unrefreshed despite adequate sleep duration, request a sleep study. CPAP (continuous positive airway pressure) is effective for OSA in CKD patients and may independently slow CKD progression. NOCTURIA (frequent nocturnal urination): In CKD, the kidneys lose the ability to concentrate urine at night (a function called urinary concentration) - producing large volumes of dilute urine including overnight. Nocturia is nearly universal in advanced CKD and is one of the strongest disruptors of sleep continuity. Management is limited but includes: adjusting diuretic timing (take furosemide in the morning, not the evening), limiting fluid intake in the 2-3 hours before bed (within prescribed limits), and ensuring the underlying CKD is as well-managed as possible. URAEMIC PRURITUS (itching): Widespread itching - particularly at night - is caused by uraemic toxin accumulation and is profoundly sleep-disruptive in dialysis patients. Management: adequate dialysis, phosphate control, moisturisers (emollients), antihistamines (with caution in CKD - sedating antihistamines at standard doses can cause excessive sedation), and newer medications including difelikefalin (Korsuva) - a peripheral kappa opioid receptor agonist approved specifically for dialysis-associated pruritus, and nalfurafine in some countries. INSOMNIA DISORDER: Primary insomnia - difficulty initiating or maintaining sleep - is more common in CKD than the general population, driven by the combination of anxiety (blood test results, disease progression), pain, nocturia, RLS, and disrupted circadian rhythms from dialysis schedules.
📌 SLEEP HYGIENE STRATEGIES THAT WORK FOR KIDNEY PATIENTS
Consistent sleep and wake times: maintaining the same bedtime and wake time 7 days a week (including weekends and non-dialysis days) is one of the most effective non-pharmacological sleep interventions. It anchors the circadian rhythm. Light management: exposure to bright light in the morning (natural daylight if possible, a light therapy lamp if not) suppresses melatonin and consolidates the circadian wake phase. Avoiding bright light and screen blue light in the hour before bed supports melatonin production and sleep onset. Temperature: sleeping in a slightly cool room (approximately 18-20 degrees C) promotes sleep by facilitating the core body temperature drop that precedes sleep onset. Fluid timing: for patients with nocturia, concentrate fluid intake in the morning and early afternoon, tapering off in the late afternoon and evening. Relaxation techniques: progressive muscle relaxation, diaphragmatic breathing, and body scan mindfulness practices activate the parasympathetic nervous system and reduce the physiological arousal that prevents sleep. These can be learned from apps, YouTube, or a cognitive behavioural therapy (CBT) for insomnia programme.
📌 CBT FOR INSOMNIA (CBT-I) - THE MOST EFFECTIVE NON-DRUG TREATMENT
Cognitive Behavioural Therapy for Insomnia (CBT-I) is now the recommended first-line treatment for chronic insomnia disorder by NICE, the American Academy of Sleep Medicine, and most major sleep guidelines - above sleeping tablets. CBT-I addresses the cognitive (anxious thoughts about sleep) and behavioural (habits that perpetuate insomnia) components of chronic insomnia through structured techniques including sleep restriction therapy, stimulus control, and cognitive restructuring. It is more effective than sleeping tablets in the long term and produces durable improvements without the dependency and side effect risks of medication. It is available as: guided sessions with a trained therapist (referral via GP), online programmes (Sleepio is evidence-based and available in the UK through the NHS), and self-help workbooks.
📌 SLEEPING TABLETS AND KIDNEY PATIENTS
Sleeping tablets require specific consideration in CKD: benzodiazepines (temazepam, diazepam) accumulate in CKD and cause excessive sedation, confusion, and fall risk - use with extreme caution and only at reduced doses. Z-drugs (zopiclone, zolpidem) similarly accumulate in advanced CKD. Melatonin is renally cleared but generally considered relatively safe at low doses in CKD for sleep onset support - discuss with your nephrologist. No sleeping tablet addresses the underlying cause of CKD-related sleep disturbance and none should be used long-term without medical review.
💬 Is insomnia a significant issue for you alongside kidney disease? Which type of sleep problem is most disruptive - restless legs, nocturia, itching, or anxiety-driven wakefulness? Share below - this community has practical lived experience that no clinical guideline captures. 💚
📚 RESOURCES
-> Sleep and CKD: niddk.nih.gov (search 'sleep problems kidney disease')
-> Restless legs syndrome in CKD: kidney.org (search 'restless legs dialysis')
-> CBT for insomnia (Sleepio): sleepio.com
